Other new agents for Hodgkin lymphoma Journal Article
| Authors: | Moskowitz, A. J.; Younes, A. |
| Article Title: | Other new agents for Hodgkin lymphoma |
| Abstract: | Brentuximab vedotin (BV) and the PD-1 inhibitors have dramatically expanded options and improved outcomes for patients with relapsed or refractory Hodgkin lymphoma (HL). For patients with disease progression following BV, PD-1 inhibitors, and autologous stem cell transplant (ASCT), treatment options are limited. Additional classes of drugs have been found to be effective for HL, including drugs that target the PI3-kinase (PI3K) pathway, histone deacetylase (HDAC) inhibitors, as well as immune modulatory agents. These agents target both the Hodgkin Reed-Sternberg cells as well as the tumor microenvironment. While these targeted drugs are options for patients who have progressed after BV or PD-1 inhibitors, there is good rationale for combining some of these agents with either BV or PD-1 inhibitors to improve response rates or durability. Such combinations are under investigation in clinical trials. Emerging therapies for HL include the anti-CD25 antibody drug conjugate, camidanlumab, as well as other therapies that target CD30 such as anti-CD30 chimeric antigen receptor (CAR)-T cells and the bispecific antibody, AFM-13. Newer targeted agents, emerging therapies, as well as studies evaluating novel combinations will be reviewed. © Springer Nature Switzerland AG 2020. |
| Keywords: | lenalidomide; hodgkin lymphoma; cd25; hdac inhibitor; car-t; pi3-kinase inhibitors |
| Journal Title: | Hematologic Malignancies |
| ISSN: | 2197-9766 |
| Publisher: | Springer |
| Date Published: | 2020-01-01 |
| Start Page: | 411 |
| End Page: | 416 |
| Language: | English |
| DOI: | 10.1007/978-3-030-32482-7_24 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Chapter 24 in "Hodgkin Lymphoma - A Comprehensive Review. 3rd ed" (ISBN: 978-3-030-32481-0) -- Export Date: 1 June 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work